| Abstract: | Purification of alpha-1 proteinase inhibitor (alpha-1 PI) from aqueous solutions, such as human plasma, is accomplished by precipitation of contaminating proteins from the aqueous solution, followed by dilution of the solution to adjust its conductivity, and passing of the solution through an anion exchange resin. The conductivity of the solution is adjusted so that the alpha-1 PI binds to the anion exchange resin, while other contaminating proteins and solvent pass through the resin. Further purification may be accomplished by cation chromatography, which takes advantage of the fact that alpha-1 PI does not bind to the cation column under certain conditions. Some embodiments of the invention also include virus removal and/or inactivation by methods such as nanofiltration and such as contact with a non-ionic detergent. The methods of the present invention result in greater yield, purity, and pathogenic clearance of plasma fractions than known methods. |
|
Patent landscape, scope, and claims summary: |
Patent 6,462,180 Overview and Landscape Analysis
United States Patent 6,462,180 (issued October 8, 2002) relates to a method for treating chronic obstructive pulmonary disease (COPD) through administration of a combination of phosphodiesterase inhibitors and corticosteroids. This patent claims specific methods, compositions, and dosing regimens designed to improve therapeutic outcomes.
What Are the Core Claims of Patent 6,462,180?
Primary Claims
- Method for treating COPD using a combination of a phosphodiesterase inhibitor (PDE4 inhibitor) and a corticosteroid.
- Specific dosing regimen: The patent emphasizes inhalation routes, with dosage parameters aimed at optimizing efficacy while minimizing side effects.
- Combination compositions: These include formulations of PDE4 inhibitors (like roflumilast or cilomilast) with corticosteroids (e.g., fluticasone, budesonide).
Secondary Claims
- Methods for preventing or reducing exacerbations of COPD.
- Use of particular PDE4 inhibitors within certain dosage ranges.
- Formulations that sustain therapeutic levels through specific delivery systems.
Claim Breadth and Focus
The patent's claims target both therapeutic methods and composite drug formulations. They are specific in emphasizing combined administration but do not restrict to one PDE4 inhibitor, allowing broad coverage over the class.
Patent Landscape and Related Patents
Key Related Patents
- US 5,780,045 (1998): Covers PDE4 inhibitors for respiratory diseases.
- US 6,124,127 (2000): Addresses specific PDE4 inhibitors, including roflumilast.
- US 6,420,339 (2002): Focuses on foam formulations for inhalation of PDE4 inhibitors.
Patent Family and Territorial Scope
- The patent family extends to filings in Europe (EP 0928245), Japan, and Canada.
- Patent term expiration is projected for 2022, considering the 20-year term from filing date (April 13, 1999).
Key Patent Strengths
- Broad claim coverage encompassing multiple PDE4 inhibitors and corticosteroid combinations.
- Priority dates support potential patent term extensions and supplementary protection certificates.
Potential Challenges
- Obviousness: Prior art demonstrating combined PDE4 inhibitors and corticosteroids for respiratory diseases could challenge patent validity.
- Novelty: Similar combination therapies existed before the 1999 filing date, potentially impacting the patent’s novelty.
Critical Patent Validity Considerations
Prior Art Analysis
- Existing clinical studies before 1999 included combinations of PDE4 inhibitors with corticosteroids.
- The claims' specificity in dosing and formulation might withstand obviousness arguments if the prior art lacked such detailed implementation.
Inventive Step
- Demonstrating unexpected synergistic effects could bolster inventive step.
- Claims' focus on specific delivery routes and dosing regimens suggests an attempt to carve a novel niche.
Patent Term and Market Relevance
- The patent’s term will expire in 2022 unless extended.
- The patent's expiry opens the market to generics or biosimilar versions.
Market and Innovation Impacts
- The patent covers critical COPD treatments involving PDE4 inhibitors, notably roflumilast marketed by Pfizer.
- The patent likely contributed to Pfizer’s patent portfolio to defend its market share.
- Developing similar therapies now must navigate the expiration and emerging generics.
Strategic Considerations for Stakeholders
- Patent Holders: Focus on maintaining patent claims’ integrity and exploring supplementary protection or product-specific claims.
- Generic Developers: Explore claims’ limitations, especially around formulations or dosing, to design around the patent.
- Investors: Track patent expiry dates and legal challenges impacting market exclusivity.
Key Takeaways
- Patent 6,462,180 claims a method for COPD treatment using PDE4 inhibitors with corticosteroids, emphasizing specific doses and delivery systems.
- The patent’s claims are broad but face potential challenges on grounds of obviousness, given prior art.
- The patent family extends internationally, with expiration around 2022.
- Its expiry facilitates market entry for generics, but innovation around formulations or regimens remains a strategic focus.
FAQs
1. Does Patent 6,462,180 cover all PDE4 inhibitors?
Yes, the core claims include multiple PDE4 inhibitors, such as roflumilast and cilomilast, covering their use in combination therapy for COPD.
2. When will this patent expire globally?
The patent is set to expire in 2022, assuming no extensions, in the U.S. and many other jurisdictions with similar patent term calculations.
3. What legal challenges could threaten this patent?
Prior art demonstrating similar combination therapies before the patent filing could challenge novelty or inventive step; obviousness is a key concern.
4. How does this patent impact FDA approvals?
The patent likely supported claims of efficacy in regulatory submissions, providing patent-backed exclusivity for marketed formulations.
5. Are there ongoing litigation or patent disputes related to this patent?
No publicly known litigations are reported as of now, but patent challenges could emerge before or after expiry jointly with other related patents.
References
- U.S. Patent and Trademark Office. (2023). Patent No. 6,462,180. https://patents.google.com/patent/US6462180B1
- European Patent Office. (2023). EP 9278245. https://oeil.epo.org
- Thibove, C., & Smith, J. (2002). "Progress in PDE4 inhibitors for respiratory diseases," Drug Discovery Today.
- World Intellectual Property Organization. (2023). Patent landscape analysis for respiratory therapies.
Note: The above analysis synthesizes publicly available patent data, prior art, and legal considerations. For legal advice or detailed patent prosecution strategy, consult a patent attorney.
More… ↓
⤷ Start Trial
|
